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the aim to improve loco-regional control and survival, 
however not at the expense of treatment related morbidity. 
Besides nodal disease detection, monitoring nodal disease 
during treatment is stil a remaining challenge. Node positions 
and volumes can change during the course of treatment 
asking for EBRT strategies that are able to follow these 
changes in order to allow tight treatment margins. 
Unfortunately the visibility of lymph nodes on cone beam CT 
images is limited and shifted and shrunken lymph nodes can 
be missed. The superior soft tissue contrast of MRI based 
position verification as realized in the concept of integrated 
MRI and linear accelerator (MR-Linac) decreases the 
uncertainties around nodal disease development during the 
course of radiotherapy, allows a more precise definition of 
nowadays accepted elective treatment margins and might 
allow an additional boost to individual lymph nodes . 
Currently, an MR-Linac system is built at the radiation 
oncology department at the UMC Utrecht, bringing the 
ultimate combination of MRI guided brachytherapy, advanced 
adapted external beam treatment with concurrent cisplatin 
based chemotherapy and MR-Linac treatment for nodal 
disease within reach for the treatment of patients with 
advanced cervical cancer. 
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For patients with cervical cancer, despite the improved dose 
conformity enabled by IMRT and VMAT, sparing of bladder, 
rectum and small bowel is still challenging because all organs 
at risk (OAR) in the pelvic area change shape and position on 
a daily basis due to variations in filling. With the introduction 
of cone-beam CT scanners it became possible to observe the 
internal organ variations of patients during each treatment 
fraction. Theoretically, this enables re-adaptation of plans 
according to tumour shrinkage and changes in OAR 
morphology, resulting in reduction of toxicity [1,2] and 
better target coverage. Full online plan adaptation requires 
that re-delineation, re-optimizing of dose distributions and 
repetition of all legally required quality assurance steps 
should be performed in a few minutes. These workload 
intensive procedures would require a high degree of 
automation and workflow-integration that is currently absent 
in off-the-shelf products.  
Nonetheless, by finding a well-balanced compromise between 
full automation and degree of plan adaptation, it is possible 
to apply a simplified scheme of adaptation that provides 
improved treatment. Based on our own experience and that 
of other research groups [3], patients can be divided into two 
groups: the first group consists of patients who show uterus 
motion as a function of bladder filling (called “Movers”) and 
the second group are those patients whose uterus position 
stays relatively stable, regardless of bladder volume (“Non-
Movers”). With a model for the uterus position, a pre-
determined set of plans (library) can be constructed for the 
“Movers” and the most appropriate treatment plan can be 
selected on a daily basis with the help of CBCT scans, while 
for the “Non-Movers” a single plan will suffice.  
The patient specific relation between bladder filling and the 
position of the uterus can be assessed by making a set of CT 
scans with full and empty bladder. A two stage approach, 
consisting of two treatment plans, one for an empty to half 
full and one for half full to full bladder, has been shown to 
give a good level of plan adaptiveness [2], ensuring both a 
good tumor coverage as sparing of the surrounding healthy 
tissue.  
Commercially available clinical software that is designed for 
organ contouring and treatment plan optimization does not 
provide solutions to generate new contours based on a 
motion model that interpolates between two extreme 
(filling) positions of an organ. We developed a MATLAB-based 
tool that allows generating intermediate contours of uterus 
as well as bladder, according to the available bladder 
volumes. Its main purpose was to interpolate linearly 
between two extreme positions and/or filling states of 
patient’s organ contours. Non-rigid deformation between one 
organ position and the other was made by matching the outer 
contour of both structures. To facilitate data handling and 
DICOM import/export options, the Matlab code was 
integrated to 3DSlicer/SlicerRT (Freeware for image 
handling) by using MatlabBridge.  
Our first adaptive patient was treated in October 2016 and in 
this presentation we will discuss our experience we gained 
since then, the challenges we encountered and the risks that 
remain with the implemented procedure. Furthermore, 
dosimetric results of different ART schemes as well as open 
issues like non-rigid dose addition for evaluation will be 
discussed.  
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The standard of care for non-metastasized locally advanced 
rectal cancer is chemo-radiotherapy combined with surgery. 
Sparing the organs at risk (OAR) with the use of state-of-the-
art planning techniques like intensity-modulated radiation 
therapy (IMRT) or volumetric modulated arc therapy (VMAT) 
is compromised by the large population-based margins that 
are necessary to compensate for the shape changes of the 
target volume over the time of treatment. In rectum 
patients, day-to-day variation in rectum and bladder filling 
often causes large deformation of the target volume, 
especially the mesorectal fat (mesorectum), which cannot be 
corrected for with a table adjustment. Minimizing shape 
changes with the use of drinking protocols to manage bladder 
filling or dietary instruction to manage bowel motion have 
been unsuccessful.  
A strategy with multiple plans made prior to treatment 
tailored to a range of possible shapes can mitigate the 
variations in target volume, by selecting the best-fitting plan 
based on daily Cone Beam CT (CBCT) scans. This strategy has 
been successfully applied in the treatment of bladder and 
cervical cancer where bladder filling is the predominant 
factor of shape changes. To create multiple plans a full and 
empty bladder pretreatment CT scan is acquired from which 
a patient specific motion model is derived which is used to 
create intermediate target volume structures.  
In rectum cancer, however, shape changes are mostly driven 
by changes in rectum volume and shape and to a much lesser 
extent by bladder filling. Because of this creating multiple 
plans based on varying bladder filling is not useful. Therefor 
our strategy to create multiple plans for plan selection is to 
apply different PTV margins to the ventral side of the 
mesorectum based on a single CT scan. This will also coop 
with the shape changes that are encountered.  
Plan selection based on daily Conebeam CT (CBCT) images 
require adequate visibility of the regions of interest. In the 
pelvic region CBCT image quality can be hampered by 
imaging artefacts caused by moving air or bowel. At the same 
time identifying the boundaries of a complex target volume 
such as the target volume for rectum cancer can be 
challenging. Uniform plan selection is realized by 
participation in an observer study where all observers 
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perform the selection procedure for a set of patients. 
Subsequently, the choices are discussed in the group of 
observers and a set of selection rules is composed. In this 
lecture we will discuss the plan selection strategy for rectum 
cancer and its introduction in the clinic. 
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Purpose or Objective: Patients with hormone-resistant 
prostate cancer (PCa) have higher biochemical failure rates 
after radiation therapy. Cyclin D1 deregulated expression in 
PCa is associated with a more aggressive disease however its 
role in radioresistance has not been determined.  
 
Material and Methods: Cyclin D1 levels in the AR-negative, 
androgen-independent PC3 and AR-positive, androgen-
independent 22Rv1 cells were stably inhibited by transfection 
with Cyclin D1-short hairpin RNA (shRNA). Tumorigenicity and 
radiosensitivity were investigated using in vitro and in vivo 
experiments.  
 
Results: Independently by AR-expression, Cyclin D1 silencing 
interfered with PCa oncogenic phenotype by inducing growth 
arrest in the G1 phase of cell cycle and reducing soft agar 
colony formation, migration, invasion, tumor formation and 
neo-angiogenesis in xenografted mice. In vitro colony 
formation and in vivo tumor growth of the PCa xenografts 
were significantly inhibited by Cyclin D1 silencing combined 
with radiotherapy. Cyclin D1 silencing radiosensitizes PCa 
cells by impairing the NHEJ and HR pathways responsible of 
the DNA double-strand break repair. Cyclin D1 directly 
interacts with activated-ATM, -DNA-PKC and RAD51 that are 
downstream targets of Cyclin D1-mediated PCa cells 
radioresistance.  
 
Conclusion: Taken together, these observations suggest a 
Cyclin D1 role in radioresistance mechanism. Cyclin D1 could 
represents a potential target for radioresistent androgen-
sensitive or not prostate cancer cells. 
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Purpose or Objective: We investigated the effects of 
eukaryotic elongation factor 2 kinase (EEF2K) in esophageal 
squamous cell carcinoma (ESCC) and its role in radiosensivity. 
 
Material and Methods: We used quantitative real-time 
polymerase chain reaction and immunohistochemistry 
analyses to compare expression of EEF2K between paired 
ESCC samples and nontumor esophageal tissues. Lentivirus 
was used to overexpress and knockdown of EEF2K gene and 
stable transmitted cell line of ECA109 and TE13 were made. 
In vitro cell counting kit 8 and clone formation assay were 
used to detect cell viability and proliferation. Wound-healing 
migration assay, transwell invasion assay three-dimensional 
culture and tube formation assay were used to investigate 
invasion, metastasis and angiogenesis of ESCC. Radioresponse 
was primary examined by clone formation assay after 
exposure of 0, 2, 4, 6, 8 Gy X-ray by a medical accelerator of 
different stable cell lines. Then apoptosis, cell-cycle arrest, 
and γ-H2AX expression were examined in 0 Gy and 8 Gy in 
the overexpressed and knockdown ESCC cell line by flow 
cytometer and immunoflourence. Gene-chips and western 
blot were used to investigate molecular mechanism. In vivo 
experiments of xenografts were used to confirm the results. 
 
Results: Levels of eEF2K were increased 52.17% of ESCC 
samples compared with matched nontumor tissues, as well as 
ESCC cell lines. Increased levels of eEF2K were associated 
with ESCC survival times of patients (P<0.05). eEF2K 
expression correlated between tumor size and TNM stage in 
primary ESCC during clinicopathological feature analysis 
(P<0.05). EEF2K promotes ESCC proliferation and 
tumorgeneity in vitro and in vivo. Improved invasion, 
metastasis and angiogenesis were also seen in EEF2K 
overexpressed cells compared with control in TE13 and 
ECA109 cell lines. An improved radioresponse was detected in 
eEF2K knockdown cells which could also be induced by 
NH125, an eEF2K inhibitor. Affymetrix GeneChip were used in 
EEF2K overexpressed ECA109 and control cells in normal 
conditions and 8 Gy of irradiation and autophagy pathways 
were detected by bioinformatic analysis. Improved protein 
expression of Atg5, mTOR, LC3, and TP53 were confirmed by 
western blot. In xengraft radiosensivity experiments, an 
enhancement factor of 1.78 was seen in ECA109 bearing nude 
mouse by NH125, along with a reduction of tumor doubling 
time. Immunohistochemistry and immunofluorescence of 
tumor tissue confirmed the molecular mechanism of 
autophagy pathway. 
 
Conclusion: EEF2K is overexpressed in ESCC and associated 
with progression and shorter survival times of patients. 
Decreased expression of EEF2K correlated with a reduction of 
malignancy in biological behavior and an improvement of 
radioresistance in ESCC, which may be mediated by 
autophagy signaling pathway. Targeting EEF2K may be a 
potential therapeutic approach of ESCC in the future. 
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Purpose or Objective: Phosphatidylinositol 4-phosphate 
(PI4P), upstream regulator of both phospholipase C 
(PLC)/Protein Kinase C (PKC) and phosphatidylinositol 3-
kinase (PI3K) / serine/threonine-protein kinases (Akt) 
pathways which control the cell motility and proliferation, is 
produced by phosphatidylinositol 4-kinase (PI4K). Thus, an 
inhibition of PI4K could inactivate these two PI4P dependent 
pathways simultaneously. In this study, we tried to identify 
that which isotype of PI4K may affect a radiosensitivity using 
RNA interference (RNAi) and also to investigate anti-hepatitis 
C viral (HCV) agents which are known to inhibit PI4K activity, 
could be repositioned as a radiosensitizer in human breast 
cancer, glioblastoma and hepatoma models. 
 
Material and Methods: A panel of human cancer cell lines 
including U251 malignant glioma cells, BT474 breast cancer 
cells, and HepG2 hepatocellular carcinoma cells were used. 
RNAi was used to specific inhibition of each isotype of PI4K 
and clonogenic assay was performed to assess the 
radiosensitizing effect of each isotype. To select an anti-HCV 
agent for pharmacologic inhibition of PI4K, IC50s of nine 
commercial antiviral agents were determined. Specific 
inhibitory effect on PI4K isotype was determined by in vitro 
kinase assay. Radiosensitizing effect of the selected anti-HCV 
agents were tested by clonogenic assay in vitro and tumor 
xenograft model in vivo, respectively. Immunoblotting, 
immunocytochemistry, and invasion/migration assay were 
performed to identify the mechanism of radiosensitization. 
 
